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Optimising the management of trachomatous trichiasis
Caused by repeated ocular infection with the bacterium 
Chlamydia trachomatis, trachoma results in blindness 
in the poorest of the poor.1 Going blind from trachoma 
is painful:2 eyelashes from scarred eyelids abrade 
the cornea, and alterations in the tear ﬁ lm make the 
cornea vulnerable to destructive secondary bacterial 
and fungal infections. Suﬀ erers often pull out their 
own misdirected eyelashes if they are unable to access, 
unwilling to request, or unaware of the availability of 
the operations that might reposition those eyelashes 
and save their sight.
In the 1937 instalment of his landmark seven-volume 
Textbook of Ophthalmology, Duke-Elder3 was moved 
to note that trachoma was “an immense subject, in 
the literature replete with hypotheses, discussions, 
polemics, in the world pregnant with suﬀ ering, disability 
and blindness”. Over the ensuing eight decades, in 
more than 50 countries,4 the suﬀ ering, disability, and 
blindness have, regrettably, endured. The world is 
fortunate that a handful of committed academic groups 
have continued to develop and test key hypotheses, 
too—and, generally, to avoid polemics. But real progress 
in the science of interventions against trachoma occurs 
infrequently, in part because funding for research on 
neglected diseases like trachoma has been very limited.
In The Lancet Global Health, the randomised 
controlled trial by Esmael Habtamu and colleagues5 
does represent real progress. It is arguably the most 
important work on trichiasis (the condition in 
which eyelashes touch the eye) since Reacher and 
colleagues,6,7 working in Oman more than two decades 
ago, established bilamellar tarsal rotation (BLTR) as the 
management option of choice. However, the trials in 
Oman did not include as a comparator the technique of 
posterior lamellar tarsal rotation (PLTR) which, despite 
a lack of head-to-head data to judge its eﬃ  cacy against 
that of BLTR, has continued to be widely used in some 
programmes in Africa. The current work provides those 
long-awaited data.
Habtamu and colleagues provide a meticulous 
comparison of BLTR and PLTR. They identiﬁ ed 
PLTR-experienced surgeons and, after training and 
certifying them in BLTR, allowed a run-in period of 
6 months and required repeat BLTR certiﬁ cation 
before commencing recruitment for the trial, to ensure 
that each surgeon was technically competent and 
experienced at both procedures. Randomisation was 
stratiﬁ ed by surgeon, to reduce any eﬀ ect of diﬀ erential 
surgical skill. The design, conduct, and analysis of the 
trial were exemplary, including exceptionally high 
follow-up rates, demonstration of repeatability of 
outcome measurement, and development and use of a 
method to assess outcomes masked to randomisation 
status—overcoming the problem posed by the 
association of one technique (BLTR) with a visible scar 
on the outer surface of the eyelid.
The diﬀ erence in outcomes is compelling. 1 year 
after surgery, the rate of recurrent trichiasis was 22% 
in those who had undergone BLTR, and 13% in those 
who had undergone PLTR: an absolute risk diﬀ erence 
of 9·50% (95% CI 4·79–14·16). This is an incredibly 
important ﬁ nding for programmes, for which the very 
high incidence of postoperative trichiasis (exceeding 
60% at 3 years in one study,8 with substantial variation 
between locations9) has for a long time represented 
a major disincentive to sign-up by prospective 
patients. Extrapolating this recurrence reduction to 
the management of the millions of people who need 
trichiasis surgery worldwide4 suggests that use of PLTR 
could help to avert hundreds of thousands of cases 
of recurrent disease: a presentation that aﬀ ords a 
management challenge even for experienced oculo-
plastic surgeons. The implication is that surgeons who 
are yet to be trained should be trained to undertake PLTR 
rather than BLTR. Whether highly BLTR-experienced 
surgeons should be asked to retrain in the alternative 
technique is a separate question that should be 
prospectively addressed.
A committed alliance4 of ministries of health, non-
governmental organisations, donors, and academics is 
now working tirelessly to try to achieve the World Health 
Assembly’s target of elimination of trachoma as a public 
health problem by 2020.10 The work by Habtamu and 
colleagues provides added impetus to that eﬀ ort.
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